Skip to main content

Advertisement

Table 3 Logistic regression model analyses of chemotherapy response in the combined cohorta

From: Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy

    Univariate analysis Multivariable analysis
Signatures n pCR rate OR Lower 95 % Upper 95 % P value auROC OR Lower 95 % Upper 95 % P value auROC
Age, years (cont. variable) 1.0 0.97 1.00 0.027 0.547 0.99 0.97 1.01 0.178 0.744
Tumor size            
 T0-T2 556 24 % 1.0 0.519 1.0
 T3-T4 353 12 % 0.8 0.55 1.02 0.071 0.6 0.50 0.84 0.001
ER IHC            
 Positive 487 11 % 1.0 0.679 1.0
 Negative 415 37 % 4.7 3.39 6.61 <0.001 1.8 0.99 3.34 0.052
PR IHC            
 Positive 393 12 % 1.0 0.643 1.0
 Negative 507 33 % 3.8 2.64 5.36 <0.001 1.1 0.65 1.89 0.716
HER2 STATUS            
 Negative 799 22 % 1.0 0.533 1.0
 Positive 88 35 % 2.1 1.30 3.30 0.002 1.3 0.64 2.51 0.492
PAM50            
 Luminal A 281 6 % 1.0 0.719 1.0
 Luminal B 168 16 % 3.0 1.57 5.64 0.001 3.3 1.72 6.45 <0.001
 HER2-E 93 37 % 8.9 4.69 17.09 <0.001 6.1 2.75 13.38 <0.001
 Basal-like 296 38 % 9.6 5.49 15.40 <0.001 6.1 2.94 12.66 <0.001
 Normal-like 72 29 % 6.4 3.16 12.96 <0.001  
STUDY            
 HORAK 253 27 % 1.0 0.553 1.0
 ISPY 54 31 % 1.2 0.65 2.32 0.532 1.3 0.55 3.16 0.540
 MDACC508 488 20 % 0.7 0.48 0.97 0.032 0.9 0.58 1.33 0.526
 MIYAKE 115 23 % 0.8 0.49 1.37 0.443 1.0 0.55 1.95 0.910
  1. aOR, Odds ratio; auROC, Area under the receiver operating curve; HER2-E, HER2-enriched; pCR, Pathological complete response; ER, Estrogen receptor; PR, Progesterone receptor; IHC, Immunohistochemistry